Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
Rallybio is shedding weight for the next leg of its race, parting ways with 45% of its staff and focusing on its two phase 2-ready programs to extend its cash runway into the middle of 2026.
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Rallybio Announces Multiple Dose Data from the Completed Phase 1 of RLYB212
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting
Rallybio to Present at the JonesTrading 2023 Healthcare Summit